Cancer Cachexia Market Size, Share, Opportunities, And Trends By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, Others), By Mechanism Of Action (Appetite Stimulators, Weight Loss Stabilizers), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), And By Geography - Forecasts From 2024 To 2029

  • Published : Feb 2024
  • Report Code : KSI061616140
  • Pages : 145

The cancer cachexia market is evaluated at US$2,058.952 million for the year 2022 growing at a CAGR of 4.78% reaching the market size of US$2,854.926 million by the year 2029.

Cancer cachexia is characterized by a decrease in appetite and muscular wasting. It is multifactorial and may be brought on by host phagocytic activity, unintentional weight loss, an unbalanced protein diet, and chronic inflammation. Treatment options for cancer cachexia include progestogens and corticosteroids. Progesterone is a steroid hormone that can be either synthetic or natural.

Driving factors for the cancer cachexia market

There has been a rise in demand for medications and treatment due to factors including the rising incidence of cancer and cancer cachexia in patients. The cancer cachexia market's increasing need for medicines has increased R&D efforts to create new therapeutic medications. These elements play a significant role in the cancer cachexia market growth. Additionally, the cancer cachexia market has grown as a result of greater knowledge of this illness and developments in the treatment of cancer cachexia.

Growing prevalence of cancer

The prevalence of cancer is rising worldwide. According to information released by the WHO in February 2022, 400,000 children are diagnosed with cancer each year, and the most prevalent malignancies differ by country. As a result, the occurrence of cancer cachexia, which is characterized by systemic inflammation, a negative protein and energy balance, and an unintentional loss of lean body mass, is rising among cancer patients. This rise is fueling the cancer cachexia market growth.

Increasing use of multidisciplinary approach and development

The National Centre for Biotechnology Information (NCBI) reports that cancer cachexia, which causes a gradual loss of adipose tissue and skeletal muscle mass, will develop in around half of all cancer patients. Patient quality of life is significantly affected by cachexia syndrome, which also has poor outcomes from therapies like chemotherapy and lower survival rates. Treatments for cachexia involve exogenic appetite stimulants, with an emphasis on symptom palliation and patient distress reduction. The earlier treatments were not very successful since they just addressed one part of this illness when a multifaceted strategy was required.

Presence of potential drugs

Various drugs are present in the market that have proven to be successful in treating cancer-induced cachexia, despite a clinical gap in the treatment results. There isn't presently a drug being approved specifically to deal with cancer cachexia. This widens the gap in treatment options, which industry players are attempting to narrow through R&D and the introduction of new drugs onto the global cancer cachexia market.

Increasing acceptance of combination treatments

Current treatments for cachexia use a multidisciplinary approach; combination therapy, which incorporates novel therapeutic agents including megestrol acetate, medroxyprogesterone, ghrelin, and omega-3 fatty acids, among others, has been merged with dietary changes and exercise. The cancer cachexia industry is anticipated to grow as a result of improvements in treatment methods.

Helsinn, a Swiss pharmaceutical company that creates top-notch cancer care and rare disease products, partnered with Ono Pharmaceutical to announce the first launch of Adlumizo (anamorelin) in Japan in 2021 to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer.

Increase in research & development

A growing amount of focus has been placed on clinical investigations to pinpoint the features of cancer cachexia across a variety of human malignancies due to the high frequency of cancer cachexia instances among cancer patients worldwide. To improve cancer outcomes, it is vital to understand the molecular processes behind muscle loss as cancer cachexia progresses. As a result, there is a huge pipeline of products and considerable R&D operations underway.

In North America, it is projected that the cancer cachexia market will grow steadily. 

The cancer cachexia market is anticipated to hold the maximum market share in North America. The dominance of this region is a result of the rising incidence of cancer cachexia and expanding knowledge of cancer-supportive therapies. This location is distinguished by a higher degree of affordability as well as the availability of patients with adequate reimbursement plans. The cancer cachexia industry in Europe is predicted to grow at a high growth rate due to rising awareness of the condition and rising treatment demand. Additionally, due to cancer cachexia market participants in Europe making sizeable expenditures to upgrade their supply chains and launch new pharmaceuticals, the market is anticipated to grow.

Market Key Developments

  • In June 2023, Actimed Therapeutics Ltd., a clinical-stage specialty pharmaceutical business located in the UK, secured more than £5 million in an oversubscribed Series A investment round. The firm is dedicated to bringing innovation to the treatment of cancer cachexia and kindred muscle-wasting conditions.
  • In September 2022, The multi-year agreement between CytoReason and Pfizer has been extended, and Pfizer will be able to use CytoReason's AI technology in its drug development initiatives.
  • In June 2022, A $25 million Cancer Grand Challenges grant has been given to Weill Cornell Medicine, the Rutgers Cancer Institute of New Jersey, and Cold Spring Harbour Laboratory to address cancer cachexia, the crippling wasting disease that accounts for up to 30% of cancer-related fatalities.

Cancer Cachexia Market Scope:


Report Metric Details
Market Size Value in 2022 US$2,058.952 million
Market Size Value in 2029 US$2,854.926 million
Growth Rate CAGR of 4.78% from 2022 to 2029
Base Year 2022
Forecast Period 2024 – 2029
Forecast Unit (Value) USD Million
Segments Covered
  • Therapeutics
  • Mechanism of Action
  • Distribution Channel
  • Geography
Companies Covered
Regions Covered North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope Free report customization with purchase



  • By Therapeutics
    • Progestogens
    • Corticosteroids
    • Combination Therapy
    • Others
  • By Mechanism of Action
    • Appetite Stimulators
    • Weight Loss Stabilizers
  • By Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Progestogens

5.3. Corticosteroids

5.4. Combination Therapy

5.5. Others


6.1. Introduction

6.2. Appetite Stimulators

6.3. Weight Loss Stabilizers


7.1. Introduction

7.2. Hospital Pharmacy

7.3. Retail Pharmacy

7.4. Online Pharmacy


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations


10.1. Actimed Therapeutics

10.2. Pephexia Therapeutics

10.3. Pfizer

10.4. Ono Pharma

10.5. Helsinn Group

10.6. Merck KGaA

10.7. Aveo Oncology

10.8. Tetra Bio-Pharma

Actimed Therapeutics

Pephexia Therapeutics


Ono Pharma

Helsinn Group

Merck KGaA

Aveo Oncology

Tetra Bio-Pharma